Chemistry, Biological Properties, and Bio-analysis of Tafamidis, a New
Transthyretin Stabilizer: A Systematic Review

Nikhil      Agarwal; Sanjay      Sharma; Jasira      Sultan

doi:10.2174/0118715257250153231011062855

Abstract

Background: Cardiomyopathy is a global health crisis that affects people all over the world. Consequently, scientists felt compelled to look for and develop ever-more-powerful pharmaceuticals. For ATTR-CM, the only drug currently recommended by the European Society of Cardiology is Tafamidis.

Objectives: The primary aim of this review article is to understand the chemistry, pharmacodynamic, pharmacokinetic, and bio-analytical methods available for Tafamidis.

Methods: A systematic review of the existing resources was accomplished up to 2022, comprising existing studies forming the database covering the existing resources from Web of Science, ScienceDirect, and PubMed.

Results: The review was based on a systematic review of all the existing studies used to formulate the database. The study also illustrated the PRISMA design that systematically analyses the prevalent resources.

Conclusion: Minimal analytical techniques are observed for quantifying the Tafamidis and transthyretin kinetic stabiliser. Therapeutic, pharmacological, and analytical considerations for the novel drug Tafamidis are discussed in this review. Particular attention is paid to the many different analytical and bioanalytical methods currently available for estimating Tafamidis, and the need is highlighted to develop a straightforward, validated technique that meets green chemistry standards.

Keywords: Tafamidis, transthyretin amyloidogenesis, transthyretin amyloid cardiomyopathy, pharmacokinetic, pharmacodynamic, analytical method.

« Previous Next »

Graphical Abstract

[1]
Verma, B.; Patel, P. Tafamidis; StatPearls Publishing: Treasure Island, FL, 2022. 

[2]
Burton, A.; Castaño, A.; Bruno, M.; Riley, S.; Schumacher, J.; Sultan, M.B.; Tai, S.S.; Judge, D.P.; Kelly, J.W. Drug discovery and development in rare diseases: Taking a closer look at the tafamidis. 2021, 1225-1243.

[3]
Monteiro, C.; Martins da Silva, A.; Ferreira, N.; Mesgarzadeh, J.; Novais, M.; Coelho, T.; Kelly, J.W. Cerebrospinal fluid and vitreous body exposure to orally administered tafamidis in hereditary ATTRV30M (p.TTRV50M) amyloidosis patients. Amyloid,  2018, 25(2), 120-128.
 [http://dx.doi.org/10.1080/13506129.2018.1479249] [PMID: 29993288]

[4]
Elliott, P.; Drachman, B.M.; Gottlieb, S.S.; Hoffman, J.E.; Hummel, S.L.; Lenihan, D.J.; Ebede, B.; Gundapaneni, B.; Li, B.; Sultan, M.B.; Shah, S.J. Circulation : Heart failure long-term survival with tafamidis in patients with transthyretin amyloid cardiomyopathy. 2022, 4-11.

[5]
Cruz, M.W. Tafamidis for autonomic neuropathy in hereditary transthyretin (ATTR) amyloidosis: A review. Clin. Auton. Res.,  2019, 29(S1)(1), 19-24.
 [http://dx.doi.org/10.1007/s10286-019-00625-9] [PMID: 31407119]

[6]
Giblin, G.T.; Cuddy, S.A.M.; Gonza, E.; Sewell, A.; Murphy, A.; Dorbala, S.; Falk, R.H. Effect of tafamidis on global longitudinal strain and myocardial work in transthyretin cardiac amyloidosis. European Heart Journal - Cardiovascular Imaging,  2022, 23(8), 1029-1039.
 [http://dx.doi.org/10.1093/ehjci/jeac049]

[7]
Marques, N.; Azevedo, O.; Almeida, A.R.; Bento, D.; Cruz, I.; Correia, E.; Lourenço, C.; Lopes, L.R. Specific therapy for transthyretin cardiac amyloidosis: A systematic literature review and evidence‐based recommendations. J. Am. Heart Assoc.,  2020, 9(19), e016614.
 [http://dx.doi.org/10.1161/JAHA.120.016614] [PMID: 32969287]

[8]
Kazi, D.S.; Bellows, B.K.; Baron, S.J.; Shen, C.; Cohen, D.J.; Spertus, J.A.; Yeh, R.W.; Arnold, S.V.; Sperry, B.W.; Maurer, M.S.; Shah, S.J. Cost-Effectiveness of tafamidis therapy for transthyretin amyloid cardiomyopathy. Circulation,  2020, 141(15), 1214-1224.
 [http://dx.doi.org/10.1161/CIRCULATIONAHA.119.045093] [PMID: 32078382]

[9]
Magrinelli, F.; Fabrizi, G.M.; Santoro, L.; Manganelli, F.; Zanette, G.; Cavallaro, T.; Tamburin, S. Pharmacological treatment for familial amyloid polyneuropathy. Cochrane Database Syst. Rev.,  2020, 4(4), CD012395.
 [PMID: 32311072]

[10]
Cristóbal Gutiérrez, H.; Pelayo-Negro, A.L.; Gómez Gómez, D.; Martín Vega, M.Á.; Valero Domínguez, M. Overview of treatments used in transthyretin-related hereditary amyloidosis: A systematic review. Eur. J. Hosp. Pharm. Sci. Pract.,  2020, 27(4), 194-201.
 [http://dx.doi.org/10.1136/ejhpharm-2018-001823] [PMID: 32587078]

[11]
Coelho, T.; Maia, L.F.; da Silva, A.M.; Cruz, M.W.; Planté-Bordeneuve, V.; Suhr, O.B.; Conceiçao, I.; Schmidt, H.H.J.; Trigo, P.; Kelly, J.W.; Labaudinière, R.; Chan, J.; Packman, J.; Grogan, D.R. Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J. Neurol.,  2013, 260(11), 2802-2814.
 [http://dx.doi.org/10.1007/s00415-013-7051-7] [PMID: 23974642]

[12]
Amass, L.; Li, H.; Gundapaneni, B.K.; Schwartz, J.H.; Keohane, D.J. Influence of baseline neurologic severity on disease progression and the associated disease-modifying effects of tafamidis in patients with transthyretin amyloid polyneuropathy. Orphanet J. Rare Dis.,  2018, 13(1), 225.
 [http://dx.doi.org/10.1186/s13023-018-0947-7] [PMID: 30558645]

[13]
Coelho, T.; Maia, L.F.; Martins da Silva, A.; Waddington Cruz, M.; Planté-Bordeneuve, V.; Lozeron, P.; Suhr, O.B.; Campistol, J.M.; Conceição, I.M.; Schmidt, H.H.J.; Trigo, P.; Kelly, J.W.; Labaudinière, R.; Chan, J.; Packman, J.; Wilson, A.; Grogan, D.R. Tafamidis for transthyretin familial amyloid polyneuropathy: A randomized, controlled trial. Neurology,  2012, 79(8), 785-792.
 [http://dx.doi.org/10.1212/WNL.0b013e3182661eb1] [PMID: 22843282]

[14]
Griffin, J.M.; Rosenblum, H.; Maurer, M.S. Pathophysiology and therapeutic approaches to cardiac amyloidosis. Circ. Res.,  2021, 128(10), 1554-1575.
 [http://dx.doi.org/10.1161/CIRCRESAHA.121.318187] [PMID: 33983835]

[15]
Tschöpe, C.; Elsanhoury, A. Treatment of transthyretin amyloid cardiomyopathy: The current options, the future, and the challenges. J. Clin. Med.,  2022, 11(8), 2148.
 [http://dx.doi.org/10.3390/jcm11082148] [PMID: 35456241]

[16]
Gertz, M.A.; Dispenzieri, A. Systemic amyloidosis recognition, prognosis, and therapy. JAMA,  2020, 324(1), 79-89.
 [http://dx.doi.org/10.1001/jama.2020.5493] [PMID: 32633805]

[17]
Drug, N. New drug: Tafamidis and tafamidis meglumine for amyloid cardiomyopathy. Aust. Prescr.,  2021, 44(4), 139.
 [http://dx.doi.org/10.18773/austprescr.2021.032] [PMID: 34421180]

[18]
Nencetti, S.; Rossello, A.; Orlandini, E. Tafamidis (Vyndaqel): A light for FAP patients. ChemMedChem,  2013, 8(10), n/a.
 [http://dx.doi.org/10.1002/cmdc.201300245] [PMID: 24000164]

[19]
de Lartigue, J. Tafamidis for transthyretin amyloidosis. Drugs Today,  2012, 48(5), 331-337.
 [http://dx.doi.org/10.1358/dot.2012.48.5.1808486] [PMID: 22645721]

[20]
European medicines agency, C. for M.P. for H.U. (CHMP). Assessment Report Vyndaqel.,  2011, 2011, 44.

[21]
Waddington Cruz, M.; Benson, M.D. A review of tafamidis for the treatment of transthyretin-related amyloidosis. Neurol. Ther.,  2015, 4(2), 61-79.
 [http://dx.doi.org/10.1007/s40120-015-0031-3] [PMID: 26662359]

[22]
Pfizer. Pfizer’s Vyndaqel® (Tafamidis) First Therapy Approved in the European Union for the Rare and Fatal Neurodegenerative Disease Transthyretin Familial Amyloid Polyneuropathy (TTR-FAP). 2011. Available From: https://www.pfizer.com/news/press-release/press-release-detail/pfizer_s_vyndaqel_tafamidis_first_therapy_approved_in_the_european_union_for_the_rare_and_fatal_neurodegenerative_disease_transthyretin_familial_amyloid_polyneuropathy_ttr_fap

[23]
Scott, L.J. Tafamidis: A review of its use in familial amyloid polyneuropathy. Drugs,  2014, 74(12), 1371-1378.
 [http://dx.doi.org/10.1007/s40265-014-0260-2] [PMID: 25022953]

[24]
Monteiro, C.; Mesgazardeh, J.S.; Anselmo, J.; Fernandes, J.; Novais, M.; Rodrigues, C.; Brighty, G.J.; Powers, D.L.; Powers, E.T.; Coelho, T.; Kelly, J.W. Predictive model of response to tafamidis in hereditary ATTR polyneuropathy. JCI Insight,  2019, 4(12), e126526.
 [http://dx.doi.org/10.1172/jci.insight.126526] [PMID: 31217346]

[25]
Serrano, D.; Atzinger, C.B.; Botteman, M.F. Understanding the disease course and therapeutic benefit of tafamidis across real-world studies of hereditary transthyretin amyloidosis with polyneuropathy: A proof of concept for integrative data analytic approaches. Neurol. Ther.,  2018, 7(1), 141-154.
 [http://dx.doi.org/10.1007/s40120-018-0096-x] [PMID: 29611130]

[26]
Yee, A.W.; Aldeghi, M.; Blakeley, M.P.; Ostermann, A.; Mas, P.J.; Moulin, M.; de Sanctis, D.; Bowler, M.W.; Mueller-Dieckmann, C.; Mitchell, E.P.; Haertlein, M.; de Groot, B.L.; Boeri Erba, E.; Forsyth, V.T. A molecular mechanism for transthyretin amyloidogenesis. Nat. Commun.,  2019, 10(1), 925.
 [http://dx.doi.org/10.1038/s41467-019-08609-z] [PMID: 30804345]

[27]
Damy, T.; Garcia-Pavia, P.; Hanna, M.; Judge, D.P.; Merlini, G.; Gundapaneni, B.; Patterson, T.A.; Riley, S.; Schwartz, J.H.; Sultan, M.B.; Witteles, R. Efficacy and safety of tafamidis doses in the TAFAMIDIS IN TRANSTHYRETIN CARDIOMYOPATHY CLINICAL TRIAL (ATTR‐ACT) and long‐term extension study. Eur. J. Heart Fail.,  2021, 23(2), 277-285.
 [http://dx.doi.org/10.1002/ejhf.2027] [PMID: 33070419]

[28]
Quock, T.P.; Yan, T.; Chang, E.; Guthrie, S.; Broder, M.S. Epidemiology of AL amyloidosis: A real-world study using US claims data. Blood Adv.,  2018, 2(10), 1046-1053.
 [http://dx.doi.org/10.1182/bloodadvances.2018016402] [PMID: 29748430]

[29]
Ruberg, F.L.; Grogan, M.; Hanna, M.; Kelly, J.W.; Maurer, M.S. Transthyretin amyloid cardiomyopathy. J. Am. Coll. Cardiol.,  2019, 73(22), 2872-2891.
 [http://dx.doi.org/10.1016/j.jacc.2019.04.003] [PMID: 31171094]

[30]
Keohane, D.; Schwartz, J.; Gundapaneni, B.; Stewart, M.; Amass, L. Tafamidis delays disease progression in patients with early stage transthyretin familial amyloid polyneuropathy: additional supportive analyses from the pivotal trial. Amyloid,  2017, 24(1), 30-36.
 [http://dx.doi.org/10.1080/13506129.2017.1301419] [PMID: 28393570]

[31]
Coelho, T.; Merlini, G.; Bulawa, C.E.; Fleming, J.A.; Judge, D.P.; Kelly, J.W.; Maurer, M.S.; Planté-Bordeneuve, V.; Labaudinière, R.; Mundayat, R.; Riley, S.; Lombardo, I.; Huertas, P. Mechanism of action and clinical application of tafamidis in hereditary transthyretin amyloidosis. Neurol. Ther.,  2016, 5(1), 1-25.
 [http://dx.doi.org/10.1007/s40120-016-0040-x] [PMID: 26894299]

[32]
Singh, B.M.; Bohara, N.; Gautam, K.; Basnet, M.; KC, S.; KC, B.; Raut, A.; Phudong, A.; Gautam, J. A systematic review of tafamidis in patients with transthyretin amyloid cardiomyopathy. Cureus,  2021, 13(9), 18221.

[33]
Zhang, Y.; Ji, M. Iodine promoted one-pot synthesis of 2-Aryl benzoxazoles from amidoximes via oxidative cyclization and ring contraction. Eur. J. Org. Chem.,  2019, 2019(45), 7506-7510.
 [http://dx.doi.org/10.1002/ejoc.201901468]

[34]
Yuan, S.; Yu, B.; Liu, H.M. New drug approvals for 2019: Synthesis and clinical applications. Eur. J. Med. Chem.,  2020, 205, 112667.
 [http://dx.doi.org/10.1016/j.ejmech.2020.112667] [PMID: 32911308]

[35]
Karumanchi, K.; Natarajan, S.K.; Gadde, S.; Vanchanagiri, K.; Moturu, K.V.R. A new synthesis of tafamidis via zinc-MsOH mediated reductive cyclisation strategy. J. Chem. Sci.,  2021, 133(2), 48.
 [http://dx.doi.org/10.1007/s12039-021-01910-9]

[36]
National center for biotechnology information. 2023. Available From: https://pubchem.ncbi.nlm.nih.gov/compound/Tafamidis

[37]
Le Bras, A. Tafamidis: A new treatment for ATTR cardiomyopathy. Nat. Rev. Cardiol.,  2018, 15(11), 652-652.
 [http://dx.doi.org/10.1038/s41569-018-0089-6] [PMID: 30214019]

[38]
Maurer, M.S.; Mann, D.L. The tafamidis drug development program. JACC Basic Transl. Sci.,  2018, 3(6), 871-873.
 [http://dx.doi.org/10.1016/j.jacbts.2018.10.001] [PMID: 30623146]

[39]
Lee, K.R.; Jeong, J.W.; Hyun, H.C.; Jang, E.; Ahn, S.; Choi, S.; Joo, S.H.; Kim, S.; Koo, T.S. Pharmacokinetics of tafamidis, a transthyretin amyloidosis drug, in rats. Xenobiotica,  2018, 48(8), 831-838.
 [http://dx.doi.org/10.1080/00498254.2017.1366575] [PMID: 28803538]

[40]
Brief, I. In brief: Tafamidis (Vyndaqel; Vyndamax) for transthyretin amyloid cardiomyopathy. Med. Lett. Drugs Ther.,  2020, 62(1590), 16.
 [PMID: 31999671]

[41]
Smerikarova, M.; Bozhanov, S; Maslarska, V. A brief review of analytical methods for the estimation of ttr kinetic stabilizers in pharmaceutical formulations and biological matrices. Int. J. Appl. Pharm.,  2022, 14-21.

[42]
Smerikarova, M.; Bozhanov, S.; Maslarska, V.; Tournev, I. Determination of tafamidis plasma concentrations in amyloidosis patients with glu89gln mutation by HPLC-UV detection. J. Chromatogr. Sci.,  2022, 60(9), 840-847.
 [http://dx.doi.org/10.1093/chromsci/bmab132] [PMID: 34897414]

[43]
Lockwood, P.A.; Le, V.H.; O’Gorman, M.T.; Patterson, T.A.; Sultan, M.B.; Tankisheva, E.; Wang, Q.; Riley, S. The bioequivalence of tafamidis 61‐mg free acid capsules and tafamidis meglumine 4 × 20‐mg capsules in healthy volunteers. Clin. Pharmacol. Drug Dev.,  2020, 9(7), 849-854.
 [http://dx.doi.org/10.1002/cpdd.789] [PMID: 32196976]

[44]
Hyun, H.C.; Jeong, J.W.; Kim, H.R.; Oh, J.H.; Lee, J.H.; Choi, S.; Kim, Y.S.; Koo, T.S. Development and validation of a liquid chromatography–tandem mass spectrometry method for the assay of tafamidis in rat plasma: Application to a pharmacokinetic study in rats. J. Pharm. Biomed. Anal.,  2017, 137, 90-95.
 [http://dx.doi.org/10.1016/j.jpba.2017.01.020] [PMID: 28107689]

[45]
Rapezzi, C.; Elliott, P.; Damy, T.; Nativi-Nicolau, J.; Berk, J.L.; Velazquez, E.J.; Boman, K.; Gundapaneni, B.; Patterson, T.A.; Schwartz, J.H.; Sultan, M.B.; Maurer, M.S. Efficacy of tafamidis in patients with hereditary and wild-type transthyretin amyloid cardiomyopathy. JACC Heart Fail.,  2021, 9(2), 115-123.
 [http://dx.doi.org/10.1016/j.jchf.2020.09.011] [PMID: 33309574]

[46]
Huber, P.; Flynn, A.; Sultan, M.B.; Li, H.; Rill, D.; Ebede, B.; Gundapaneni, B.; Schwartz, J.H. A comprehensive safety profile of tafamidis in patients with transthyretin amyloid polyneuropathy. Amyloid,  2019, 26(4), 203-209.
 [http://dx.doi.org/10.1080/13506129.2019.1643714] [PMID: 31353964]

[47]
Çakar, A.; Durmuş-Tekçe, H.; Parman, Y. Familial amyloid polyneuropathy. Noro Psikiyatri Arsivi,  2019, 56(2), 150-156.
 [PMID: 31223250]

[48]
Ando, Y.; Coelho, T.; Berk, J.L.; Cruz, M.W.; Ericzon, B.G.; Ikeda, S.; Lewis, W.D.; Obici, L.; Planté-Bordeneuve, V.; Rapezzi, C.; Said, G.; Salvi, F. Guideline of transthyretin-related hereditary amyloidosis for clinicians. Orphanet J. Rare Dis.,  2013, 8(1), 31.
 [http://dx.doi.org/10.1186/1750-1172-8-31] [PMID: 23425518]

Rights & Permissions Print Cite

Article Metrics

51

3

Journal Information

For Authors

For Editors

For Reviewers

Explore Articles

Open Access

Open Access Articles

For Visitors

DOI https://dx.doi.org/10.2174/0118715257250153231011062855	Print ISSN 1871-5257
Publisher Name Bentham Science Publisher	Online ISSN 1875-6182

Cardiovascular & Hematological Agents in Medicinal Chemistry

Chemistry, Biological Properties, and Bio-analysis of Tafamidis, a New Transthyretin Stabilizer: A Systematic Review

Abstract

Graphical Abstract

Related Journals

Related Books

Related Articles